BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

ABBV upcoming catalysts

AbbVie: 10 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (4 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 35 readout(s) and 14 FDA event(s). Subscribe to ABBV (.ics).

Drugs: ABBV-RGX-314, Upadacitinib, Lutikizumab, Venetoclax, Ranibizumab, Bevacizumab, Livmoniplimab, Budigalimab, Mirvetuximab Soravtansine, Topical Steroid, Aflibercept, Adalimumab, ABBV-400, Folinic Acid, Fluorouracil, Irinotecan, Durvalumab, Atezolizumab, Tremelimumab, Azacitidine, IMGN632, Lubricating, Prednisolone acetate ophthalmic suspension 1%, Brimonidine tartrate ophthalmic, MEDI0618, Ravagalimab, Dupilumab, Lenvatinib, Sorafenib, Carboplatin, Obinutuzumab, AGN-151586, Risankizumab, Pomalidomide, Dexamethasone

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2/P3AbbVie ABBVNCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDAMD; nAMD; Wet Age-related Macular Degeneration; wAMD; Wet AMD; CNV; Neovascular AMD; Neovascular Agactive not recruiting671
2026-12 est.P2AbbVie ABBVNCT06107413 Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable MetUnresectable Metastatic Colorectal Canceractive not recruiting280
2026-12 est.P3AbbVie ABBVNCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativaactive not recruiting1400
2027-01 est.P2/P3AbbVie ABBVNCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as aHepatocellular Carcinomaactive not recruiting89
2027-01 est.P3AbbVie ABBVNCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to SevereAtopic Dermatitisactive not recruiting99
2027-02 est.P1/P2AbbVie ABBVNCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaAcute Myeloid Leukemiaactive not recruiting218
2027-02 est.P2AbbVie ABBVNCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High FolRecurrent Ovarian Cancer; Folate Receptor-Alpha Positiveactive not recruiting108
2027-02 est.P2AbbVie ABBVNCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis ReceivinHidradenitis Suppurativa; Atopic Dermatitisrecruiting60
2027-02 est.P2AbbVie ABBVNCT06602479 A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigraineMigraineactive not recruiting309
2027-02 est.P2AbbVie ABBVNCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisRheumatoid Arthritisrecruiting180

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-23FDA approvalapprovedABBVIE INC ABBVSKYRIZIApproved 2026-10-23: SKYRIZI (BLA761105 SUPPL53)
2026-09-25FDA approvalapprovedABBVIE ABBVJUVMOApproved 2026-09-25: JUVMO; JUVMO (COPACKAGED) (NDA220415 ORIG1)
2026-06-26FDA approvalapprovedABBVIE INC ABBVSKYRIZIApproved 2026-06-26: SKYRIZI (BLA761105 SUPPL45)
2026-06-12FDA approvalapprovedABBVIE INC ABBVSKYRIZIApproved 2026-06-12: SKYRIZI (BLA761105 SUPPL44)
2026-05-27FDA approvalapprovedABBVIE INC ABBVDECNUPAZApproved 2026-05-27: DECNUPAZ (BLA761460 ORIG1)
2026-05-21FDA approvalapprovedABBVIE ABBVLINZESSApproved 2026-05-21: LINZESS (NDA202811 SUPPL23)
2026-05-20FDA approvalapprovedABBVIE ABBVVENCLEXTAApproved 2026-05-20: VENCLEXTA (NDA208573 SUPPL32)
2026-04-22Complete response lettercomplete responseAbbVie Inc. ABBVAGN-151586CRL 2026-04-22: AbbVie Inc. BLA 761459 (AGN-151586 for injection)
2026-03-06FDA approvalapprovedABBVIE INC ABBVSKYRIZIApproved 2026-03-06: SKYRIZI (BLA761105 SUPPL42)
2026-02-19FDA approvalapprovedABBVIE ABBVVENCLEXTAApproved 2026-02-19: VENCLEXTA (NDA208573 SUPPL31)
2025-12-18FDA approvalapprovedABBVIE ABBVVRAYLARApproved 2025-12-18: VRAYLAR (NDA204370 SUPPL17)
2025-12-18FDA approvalapprovedABBVIE ABBVVRAYLARApproved 2025-12-18: VRAYLAR (NDA204370 SUPPL15)
2025-12-18FDA approvalapprovedABBVIE ABBVVRAYLARApproved 2025-12-18: VRAYLAR (NDA204370 SUPPL16)
2025-12-18FDA approvalapprovedABBVIE ABBVVRAYLARApproved 2025-12-18: VRAYLAR (NDA204370 SUPPL14)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2AbbVie ABBVNCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized AnxGeneralized Anxiety Disorder (GAD)recruiting315
2026-11 est.P3AbbVie ABBVNCT06389136 A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabAtopic Dermatitisactive not recruiting184
2026-11 est.P2AbbVie ABBVNCT05822752 Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab Hepatocellular Carcinomaactive not recruiting130
2026-11 est.P2AbbVie ABBVNCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancHigh Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Canceractive not recruiting125
2026-11 est.P2AbbVie ABBVNCT04895436 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring ChronicChronic Lymphocytic Leukemia (CLL)recruiting75
2026-10-13P2AbbVie ABBVNCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-Related Macular Degeneration (nAMD)active not recruiting146
2026-10 est.P2AbbVie ABBVNCT07730554 A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult ParticipantsForehead Linesactive not recruiting84
2026-10 est.P3AbbVie ABBVNCT05407636 Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDAMD; nAMD; Wet Age-related Macular Degeneration; wAMD; WetAMD; CNVactive not recruiting735
2026-09-03P3AbbVie ABBVNCT07032597 A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult ParticipantsMid Face Volume Deficitcompleted252
2026-09 est.P3AbbVie ABBVNCT06100744 A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) ReceiJuvenile Psoriatic Arthritisrecruiting40
2026-08-21P3AbbVie ABBVNCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult ParticipanDry Eye Diseasecompleted261
2026-08-17P2AbbVie ABBVNCT03339128 Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenIrritable Bowel Syndromecompleted272
2026-08 est.P3AbbVie ABBVNCT03539744 A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in ParticiMultiple Myelomaactive not recruiting265
2026-07-27P2AbbVie ABBVNCT06236880 A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDDMajor Depressive Disordercompleted126
2026-07-19 est.P3AbbVie ABBVNCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisUlcerative Colitis (UC)withdrawn
2026-07-15P3AbbVie ABBVNCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to SeRheumatoid Arthritiscompleted487
2026-07-14P3AbbVie ABBVNCT05995340 ELAPR002f Injectable Gel in the Treatment of Atrophic Acne ScarsAtrophic Acne Scarscompleted157
2026-07 est.P2AbbVie ABBVNCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary PeritoneAdvanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancersrecruiting110
2026-07 est.P2AbbVie ABBVNCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNon-small Cell Lung Canceractive not recruiting270
2026-06-29P3AbbVie ABBVNCT06806293 Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineMenstrual Migraine (MM)active not recruiting468
2026-06-19P3AbbVie ABBVNCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SROpen-Angle Glaucoma; Ocular Hypertensioncompleted455
2026-06-18P2AbbVie ABBVNCT04567550 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME)completed139
2026-05 est.P1/P2AbbVie ABBVNCT03933735 A Study of TNB-383B in Participants With Relapsed or Refractory Multiple MyelomaMultiple Myelomaactive not recruiting220
2026-04-27P3AbbVie ABBVNCT04750226 Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced ParkinParkinson's Disease (PD)completed118
2026-04-17P3AbbVie ABBVNCT04379050 Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With ParkinsParkinson's Disease (PD)completed130
2026-04-03P3AbbVie ABBVNCT06794866 A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult PForehead Linescompleted150
2026-02-05P2/P3AbbVie ABBVNCT06547125 A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin QualSkin Quality Deficitcompleted135
2026-02-04P3AbbVie ABBVNCT05411198 Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years oOpen-Angle Glaucomacompleted74
2026-01-26P2AbbVie ABBVNCT04295538 Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With AcuSpinal Cord Injury (SCI)completed60
2026-01-05 est.P3AbbVie ABBVNCT06390722 A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic DermatitisAtopic Dermatitis; Sleep Disturbancewithdrawn
2025-12-05P3AbbVie ABBVNCT05818709 A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult ParticipantsFacial Volume Deficitcompleted61
2025-12-01P3AbbVie ABBVNCT04760769 Open-label Trial in Parkinson's Disease (PD)Parkinson Diseasecompleted992
2025-11-25P3AbbVie ABBVNCT06387394 A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle ProminenceMasseter Muscle Prominencecompleted202
2025-11-20P3AbbVie ABBVNCT06068855 A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult ParticipantsMasseter Muscle Prominencecompleted249
2025-11-19P2AbbVie ABBVNCT05291234 A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-9Alzheimer's Disease (AD)completed106

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.